Literature DB >> 24566847

Long-term results of the Ross operation: an 18-year single institutional experience.

Francisco Diniz Affonso da Costa1, Johanna Josepha Maria Takkenberg2, Daniele Fornazari3, Eduardo Mendel Balbi Filho3, Claudinei Colatusso3, Mohammad Mostafa Mokhles2, Ana Beatriz Brenner Affonso da Costa3, Andressa Gervasoni Sagrado3, Andreia Dumsch de Aragon Ferreira3, Tiago Fernandes3, Sergio Veiga Lopes3.   

Abstract

OBJECTIVES: The purpose of the study was to assess the 18-year outcome of the Ross operation (RO), with emphasis on survival, reoperations, and late function of the pulmonary autografts (PAs) and the right-sided pulmonary allografts.
METHODS: Between May 1995 to July 2013, 414 patients with a mean age (mean ± standard deviation) of 30.8 ± 13.1 years were submitted to an RO with the root replacement (n = 356) or the inclusion (n = 58) technique. The most prevalent aetiology was bicuspid valve (n = 206, 49.8%). Patients were divided in four groups depending on the type of allograft used on the right side. The mean follow-up was 8.2 ± 5.2 years and was 97.7% complete. In addition to longitudinal outcomes determined by means of the Kaplan-Meier analysis, log-rank test and Cox regression analysis were used to identify predictors of valve failure.
RESULTS: The early mortality rate was 2.7% and the late survival rate was 89.3% at 15 years, similar to an age- and sex-matched population. There were 22 reoperations on the PA (90.7% freedom at 15 years) and 15 on the pulmonary allografts (92.5% freedom at 15 years). The freedom rate from more than mild aortic insufficiency (AI) was 73.1% at 15 years. Thirty-three patients presented with a late root diameter >45 mm, corresponding to a freedom rate of 72.4% at 15 years. Patients with AI and a dilated annulus, especially males, are at greater risk for these complications. Among the right-sided allografts, fresh decellularized allografts showed significantly superior freedom from structural valve dysfunction.
CONCLUSIONS: The RO was associated with excellent long-term survival and low incidence of reoperations up to 15 years. Male patients with AI and dilated annulus are at increased risk for late insufficiency and root dilatation. Fresh decellularized allografts presented the best results for reconstruction of the right ventricular outflow tract.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Decellularization; Pulmonary autograft; Surgery; Tissue engineering; Valves

Mesh:

Year:  2014        PMID: 24566847     DOI: 10.1093/ejcts/ezu013

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  15 in total

1.  Development and Characterization of a Porcine Mitral Valve Scaffold for Tissue Engineering.

Authors:  M Granados; L Morticelli; S Andriopoulou; P Kalozoumis; M Pflaum; P Iablonskii; B Glasmacher; M Harder; J Hegermann; C Wrede; I Tudorache; S Cebotari; A Hilfiker; A Haverich; Sotirios Korossis
Journal:  J Cardiovasc Transl Res       Date:  2017-05-01       Impact factor: 4.132

2.  Ross Procedure vs Mechanical Aortic Valve Replacement in Adults: A Systematic Review and Meta-analysis.

Authors:  Amine Mazine; Rodolfo V Rocha; Ismail El-Hamamsy; Maral Ouzounian; Bobby Yanagawa; Deepak L Bhatt; Subodh Verma; Jan O Friedrich
Journal:  JAMA Cardiol       Date:  2018-10-01       Impact factor: 14.676

3.  Initial Surgical Experience with Aortic Valve Repair: Clinical and Echocardiographic Results.

Authors:  Francisco Diniz Affonso da Costa; Daniele de Fátima Fornazari Colatusso; Ana Claudia Brenner Affonso da Costa; Eduardo Mendel Balbi Filho; Vinicius Nesi Cavicchioli; Sergio Augusto Veiga Lopes; Andrea Dumsch de Aragon Ferreira; Claudinei Collatusso
Journal:  Braz J Cardiovasc Surg       Date:  2016-04

4.  The Ross procedure: time for a hard look at current practices and a reexamination of the guidelines.

Authors:  Ismail El-Hamamsy; Ismail Bouhout
Journal:  Ann Transl Med       Date:  2017-03

5.  Ross operation after failure of aortic valve repair.

Authors:  Karen B Abeln; Vincent Chauvette; Nancy Poirier; Shunsuke Matsushima; Ismail El-Hamamsy; Hans-Joachim Schäfers
Journal:  Ann Cardiothorac Surg       Date:  2021-07

6.  Surgery of the aortic root: should we go for the valve-sparing root reconstruction or the composite graft-valve replacement is still the first choice of treatment for these patients?

Authors:  Fernando de Azevedo Lamana; Ricardo Ribeiro Dias; Jose Augusto Duncan; Leandro Batisti de Faria; Luiz Marcelo Sa Malbouisson; Luciano de Figueiredo Borges; Charles Mady; Fábio Biscegli Jatene
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jul-Sep

7.  Decellularized fresh homografts for pulmonary valve replacement: a decade of clinical experience.

Authors:  Samir Sarikouch; Alexander Horke; Igor Tudorache; Philipp Beerbaum; Mechthild Westhoff-Bleck; Dietmar Boethig; Oleg Repin; Liviu Maniuc; Anatol Ciubotaru; Axel Haverich; Serghei Cebotari
Journal:  Eur J Cardiothorac Surg       Date:  2016-03-24       Impact factor: 4.191

8.  Decellularized aortic homografts for aortic valve and aorta ascendens replacement.

Authors:  Igor Tudorache; Alexander Horke; Serghei Cebotari; Samir Sarikouch; Dietmar Boethig; Thomas Breymann; Philipp Beerbaum; Harald Bertram; Mechthild Westhoff-Bleck; Karolina Theodoridis; Dmitry Bobylev; Eduard Cheptanaru; Anatol Ciubotaru; Axel Haverich
Journal:  Eur J Cardiothorac Surg       Date:  2016-02-18       Impact factor: 4.191

9.  Decellularization of human donor aortic and pulmonary valved conduits using low concentration sodium dodecyl sulfate.

Authors:  Tayyebeh Vafaee; Daniel Thomas; Amisha Desai; Louise M Jennings; Helen Berry; Paul Rooney; John Kearney; John Fisher; Eileen Ingham
Journal:  J Tissue Eng Regen Med       Date:  2017-05-12       Impact factor: 3.963

10.  In Vivo Response of Acellular Porcine Pericardial for Tissue Engineered Transcatheter Aortic Valves.

Authors:  Reza Khorramirouz; Jason L Go; Christopher Noble; David Morse; Amir Lerman; Melissa D Young
Journal:  Sci Rep       Date:  2019-01-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.